| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_a1dfd39878009ed672c93ba0247ee666 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P15-10 |
| filingDate |
1997-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_098ab71e7f43ce19fafa72ae33b0f03a
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0fd83dbe9afd7991c46f2c773b22c91c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e19442f0ab85809a16764b042785fd72 |
| publicationDate |
1997-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2391818-A1 |
| titleOfInvention |
Antagonism of endothelin actions |
| abstract |
The mechanism of hypertension following acute NO synthase blockade is via endothelin-mediated vasoconstriction. Thus, NO appears to inhibit endothelin activity by blocking its expression and not as a chronic direct acting vasodilator. Administration of an endothelin antagonist to a patient in a 'normal' physiological state may result in specific regional vasodilation. This treatment finds utility in the treatment of erectile dysfunction. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007137980-A1 |
| priorityDate |
1996-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |